Xilio Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2020 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Xilio Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2020 to Q4 2023.
  • Xilio Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $93M, a 30.9% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $93M +$22M +30.9% Dec 31, 2023 10-K 2024-04-01
Q4 2022 $71M +$24.3M +51.9% Dec 31, 2022 10-K 2024-04-01
Q4 2021 $46.7M +$21.7M +86.5% Dec 31, 2021 10-K 2023-03-02
Q4 2020 $25.1M Dec 31, 2020 10-K 2022-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.